By Laura Lutz
Des Moines, July 19 - Alchemica settled an oversubscribed private placement of shares for A$15.2 million.
The company sold 19 million shares at A$0.80 each.
U.S. institutions bought 12.5 million of the shares and existing Australian institutional shareholders about 6.5 million.
ABN Amro Morgans and Blueprint Life Sciences Group, LLC were the agents.
Proceeds will be used for development of the company's HyCAMP treatment for colorectal cancer and its HyACT cancer drug delivery platform.
Alchemica is a biopharmaceutical company based in Brisbane, Australia.
| Issuer: | Alchemica
|
| Issue: | Shares
|
| Amount: | A$15.2 million
|
| Shares: | 19 million
|
| Price: | A$0.80
|
| Warrants: | No
|
| Agents: | ABN Amro Morgans; Blueprint Life Sciences Group, LLC
|
| Settlement date: | July 19
|
| Stock symbol: | Australia: ACL
|
| Stock price: | A$0.895 at close July 19
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
